Here are three points:
1. In addition to Richard Gorelick, four other Integra LifeSciences executives reported share trades in the last month.
2. The company has a one-year high of $72.05 and a one-year low of $54.75.
3. The company’s consensus rating is “strong buy” and the average price target is $79.67 from all the analysts covering the stock.
More articles on devices:
Spineology releases Palisade Pedicular Fixation System: 4 key notes
Spinal Simplicity invests with Nueterra — 5 notes
Bone Therapeutics completes recruitment for next phase of spinal fusion study: 4 points
